Eloralintide vs Cagrilintide

Both are long-acting amylin analogues built for weekly dosing. Eloralintide was engineered to be selective for amylin receptors, while cagrilintide also acts at calcitonin receptors and is best known in combination with semaglutide (CagriSema). Eloralintide reached a 48-week phase 2 trial published in 2025; cagrilintide is further along, with phase 3 combination data.

HPLC tested · JanoshikJanoshik CertificatesNationwide DeliveryResearch Only

Eloralintide

Eloralintide (LY3841136) is an investigational, selective, long-acting amylin-receptor agonist.

BEST STUDIED FOR

Selective amylin-receptor metabolic research

R2 999View product →

🧪

Cagrilintide

A long-acting amylin analogue, studied alone and in a fixed combination with semaglutide (CagriSema).

BEST STUDIED FOR

Incretin & metabolic

Read the cited profile →

Side by side · to buy

Price, purity and dispatch

Compare	Eloralintide15mg	Cagrilintide
Price	R2,999	—
Cost per mg	R200 / mg	—
Purity (Janoshik)	On request	—
Stock	Restocking	—
Dispatch	When restocked	—
Certificate	Request CoA	—
Literature	4 papers →	—
Research focus	Selective amylin-receptor metabolic research	Incretin & metabolic
	Notify me	Read the cited profile

Prices are read live from the catalogue. Cost per mg is the vial price over its stated mg. Purity is shown only where the certificate is published. Every compound is supplied for laboratory research only.

SIDE BY SIDE

	Eloralintide	Cagrilintide
The key difference	Selective amylin-receptor agonist (Lilly)	Non-selective amylin/calcitonin analogue (Novo)
Class	Incretin & metabolic	Incretin & metabolic
Mechanism	Eloralintide (LY3841136) is an investigational, selective, long-acting amylin-receptor agonist.	Amylin is a pancreatic hormone co-secreted with insulin that induces satiety and slows gastric emptying.
Status	Investigational selective amylin-receptor agonist (Eli Lilly); phase 2 published, phase 3 under way. Not approved anywhere.	Phase 2 monotherapy data (2021) and phase 3 combination trials with semaglutide (REDEFINE, 2025–2026). Not yet approved.
Reported safety signals	The phase 2 report describes the gastrointestinal tolerability profile expected of the amylin class; no long-term data.	Trials report the gastrointestinal profile expected of the incretin/amylin class; the phase 1b study characterised tolerability of the combination.
A key study	Describes eloralintide’s discovery and pharmacology through to clinical proof of concept. (Mol Metab 2025, PMID 41109426)	A phase 2 dose-finding trial measured cagrilintide’s dose–response on body weight, safety and tolerability. (Lancet 2021, PMID 34798060)

WHEN TO RESEARCH WHICH

Cagrilintide has the larger dataset, mostly as a combination; eloralintide is the newer, receptor-selective amylin agonist studied as a single agent. Both are discussed here strictly as research compounds; nothing on this page is medical advice or a dosing guide.

REFERENCES (PUBMED)

[Eloralintide] Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept — Mol Metab 2025. PMID 41109426
[Eloralintide] Eloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept — Diabetes Obes Metab 2026. PMID 41559929
[Eloralintide] Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial — Lancet 2025. PMID 41207310
[Cagrilintide] Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial — Lancet 2021. PMID 34798060
[Cagrilintide] Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity — N Engl J Med 2025. PMID 40544433
[Cagrilintide] Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes — N Engl J Med 2025. PMID 40544432

FREQUENTLY ASKED

What is the difference between Eloralintide and Cagrilintide?

What is the regulatory status of Eloralintide and Cagrilintide?

Eloralintide: Investigational selective amylin-receptor agonist (Eli Lilly); phase 2 published, phase 3 under way. Not approved anywhere. Cagrilintide: Phase 2 monotherapy data (2021) and phase 3 combination trials with semaglutide (REDEFINE, 2025–2026). Not yet approved.

What safety signals have been reported?

Eloralintide: The phase 2 report describes the gastrointestinal tolerability profile expected of the amylin class; no long-term data. Cagrilintide: Trials report the gastrointestinal profile expected of the incretin/amylin class; the phase 1b study characterised tolerability of the combination.

Which studies is this comparison based on?

For Eloralintide: “Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept” (PMID 41109426); “Eloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept” (PMID 41559929); “Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial” (PMID 41207310). For Cagrilintide: “Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial” (PMID 34798060); “Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity” (PMID 40544433); “Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes” (PMID 40544432).